Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Climacteric”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMedDate not supplied

[Blood levels of testosterone and its urinary excretion in women of reproductive age both neurosis-free during the climacteric period and with climacteric neuroses].

Blood testosterone content was studied by the radioimmunological method in 12 healthy women (5 of reproductive age, and 7 with climacteric age changes) and in 4 patients at the postmenopause suffering from climateric neurosis. Urinary excretion of testosterone glucuronide was studied by means of fluorometry in 11 healthy women (4 of reproductive age, and 7 at the climacteric) and in 6 patients at the postmenopause with climacteric neurosis. Healthy women of reproductive age displayed marked individual variations in the blood testosterone content both during the folliculin and the lutein cycle phases. The indices of urinary testosterone excretion varied in this group lees. As to healthy women with age climacteric changes and a regular cycle and those during the postmenopause--they showed marked variations both in blood testosterone content and in urinary testosterone excretion. There were no significant differences in the indices studied in healthy women of reproductive age and in healthy women with age climacteric changes. But in 8 of 11 women with climacteric neurosis blood testosterone content and urinary testosterone excretion were much greater than the upper borders of its variations in healthy women.

Adult↗
PubMed1976

[Climacteric disturbances. 2. Therapy of climacteric disturbances].

After defining the terms climacterium and menopause the causes of climacteric disturbances are explained. During the premenopausal stage disturbances of the cycle are prevailing, caused by an insufficiency of the corpus luteum. Of climacteric disturbances should be spoken only after menopause. They are divided into: vegetative disturbances, troubles of metabolism, cardiovascular dysregulation, psychic deviations, sexual troubles and changes of the skin. The therapy of disturbances during the premenopausal stage mainly consists of the substitution of progesterone or in a cycle-like estrogen-progesterone-therapy. In the premenopausal stage estrogens are the therapy of choice. Among orally efficient estrogens the conjugated estrogen and the estradiol-valerianat are preferred. Side-effects and contraindications are discussed in detail. Among gynecologists there exists no disagreement about the necessity of therapy of serious climacteric disturbances, the opinions about prophylactic estrogen-therapy in women differ.

Climacteric↗
PubMedDate not supplied

[Excretion in the urine of glucuronides of testosterone and androstenedione in women with climacteric neurosis and without neurosis].

The author elaborated a method of study of the urinary excretion of the testosterone and androstendione glucoronides and applied it in 20 women (4 healthy women of reproductive age, 10 women at the postmenopause with a climacteric neurosis, and 7 healthy women during the climacteric). In healthy women the mean values of testosterone and androstendione urinary excretion showed no significant difference from those in women of the reproductive age and during the climacteric. It is supposed that the level of urinary excretion of these hormones showed but little change with the progress of age. As to women with a climacteric neurosis, there was no significant change of the mean values of urinary excretion to testosterone and androstendione in comparison with healthy women of the same age. This suggests that the androgenic function of the adrenal glands in this neurosis showed no significant change. Patients with a climacteric neurosis displayed higher variations in the values of the urinary excretion of testosterone and androstendione glucoronides, which was possibly associated with disturbances of regulation of the production of the androgens by the hypothalamic centres.

Adult↗
PubMed1992

[Oral symptoms in the climacteric. A prevalence study].

The female climacteric is attributed to physiological ovarian failure with the consequent decrease in the secretions of oestrogen, progestones and androgens. Numerous metabolic, psychological and physical changes have been associated with this event. Oral discomfort, including the burning mouth syndrome and the dry mouth syndrome, has been described as a menopausal symptom. However, the relationship between the hormonal changes related to climacteric and the onset of oral discomfort is still controversial. The purpose of the present study was to evaluate the prevalence of oral symptoms, with particular regard to burning sensation, xerostomia, altered taste and recurrent oral ulcerations. The relationship between oral and climacteric symptoms and psychological status of the patients was also evaluated. A questionnaire was administered to 136 women (mean age: 51.2 years, range 40-62) being consecutively referred to the University Hospital Menopause Clinic from October 1991 to March 1992. The questionnaire included informations regarding menopausal state, oral symptoms, drug assumption, wearing of partial or total dentures, parafunctions (lip and cheek biting, bruxism, tongue thrusting). Climacteric symptoms including flushes/sweats, palpitations, headache, arthralgia/myalgia, vaginal dryness, decreased concentration, tiredness, decreased libido, insomnia, vertigo were evaluated. Visual analogue scale (VAS) was used where appropriate. Information regarding the alteration of the psychological status was collected by means of the Hospital Anxiety and Depression Scale Statistical analysis was performed by chi 2 test or Fisher's Exact Probability Test and Mann-Whitney U-test. The level of significance accepted was 5%. The subjects in this study were divided into two groups on the basis of their answers to the questionnaire: group I (no. 39), premenopausal women; group II (no. 97), menopausal women.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1975

Age at the menopause and onset of the climacteric in women of Martin District, Czechoslovkia. Statistical survey and some biological and social correlations.

In this study, 6877 women were analysed whose ages ranged between 38 and 58 (born between 1909 and 1929) and who had had no artificial menopause. This is 88.04% of the total female population in this actual period of life, living in Martin District in 1967. The mean age at the menopause was found, by status quo method, to be 51.21 years (standard deviation 4.4), and by the method of weighted arithmetical means, 48.81 years, (standard deviation 3.9). The mean age at the onset of the climacteric, calculated by the same methods, was 47.55 years, or 46.74 years, respectively. The mean age at menarche was 14.6 years. The average birth-rate was 2.8. The mean period of fertility for the series as a whole was 36.6 years. Women with menstrual disturbances had their menopause about 1 year earlier. We have noted a similar tendency in nulliparas and primiparas. We could find no great difference in the age at menopause between those who had had an early or a late menarche. Menstrual disturbances also influenced the onset of the climacteric. It was at least one year earlier than with regular menstruation. Age at menarche and parity had no effect on the age at the onset of climacteric. Women working in agriculture and housewives had their menopause a little later than mean age of the series, whereas manual workers and those in other occupational categories had their menopause and onset of the climacteric about 1 year earlier. Furthermore, single women had their menopause about one year earlier than the married ones. Widows had their menopause twice so often as the married women and they got it very soon after the husbands's death.

Adult↗
PubMed1979

[Use of the bicycle ergometric test in the differential diagnosis of climacteric cardiopathy].

Bicycle ergometry on the "Elema" electrical bicycle ergometer was conducted on 6, patients of climacteric age (41 to 55 years) with pain in the region of the heart and ECG changes. The method made it possible to confirm the diagnosis of climacteric cardiopathy in 39 and to reveal climacteric cardiopathy and concurrent ischemic heart disease in 23 patients. It was noted that physical load had a favourable effect on processes of repolarization in the myocardium of patients with climacteric cardiopathy.

Adult↗
PubMed1977

Correlation between climacteric symptoms and serum levels of estradiol, progesterone, follicle-stimulating hormone, and luteinizing hormone.

Correlation between the climacteric symptoms and serum levels of estradiol. progesterone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) was studied in 191 premenopausal and postmenopausal women. Significant correlation was obtained between the climacteric symptoms represented by the menopausal index of Kupperman and associates and serum levels of estradiol as well as LH in a subgroup of the premenopausal women, ages 35 to 39 years. The symptoms were shown to be significantly related in serum levels of LH and inversely related to estradiol. These results confirmed that climacteric symptoms, at least in premenopausal women 35 to 39 years of age, could result from a low output of ovarian estrogen and a high production of pituitary gonadotropin.

Adult↗
PubMed1992

[One-year follow-up of women treated with transdermal administration of estrogen for post-castration and climacteric syndromes].

Having gained preliminary knowledge in a selected group of 64 patients treated for three months by a transcutaneous form of estrogen therapy (Estraderm TTS) for postcastration and climacteric syndromes, the authors report in this paper on the results of a one-year follow-up of a series of 42 patients treated by ETTS 25 and 50 for the same diagnoses. Administration of ETTS makes it possible to take advantage of the therapeutic transdermal system for the transfer of 17 beta-estradiol directly into the blood stream. Estradiol in a daily dose of 25, 50 or 100 microgrammes is deposited in ethanol gel as a reservoir in a special sticking tape. From there it is absorbed across a microsporous membrane by molecular diffusion into the subcapillary plexus at a constant speed till an equilibration of the diffusion gradient between skin and the system is attained. For the aim of this study is to evaluate both the recession of the subjective as well as objective complaints in patients suffering from postcastration and climacteric syndromes and the reflection of the treatment in the blood levels of gonadotropins, estrogens, gestagens and cortisol and likewise the vaginal hormonal cytology. Both the systemic and local side-effects of treatment are subject to a careful study. On the basis of a comprehensive statistical study of these changes in every patient as well as in the whole series in the course of one year the authors reach the conclusion that the ETTS administration strikingly improves the subjective as well as objective complaints of the patients, and, in agreement with the literary data, objectively influences the laboratory results concerning especially the circulating levels of gonadotropins and of estradiol. In conclusion, the authors comment on the favourable contribution of this form of treatment to gynaecological practice in the therapy of postcastration, climacteric and estrogen-losing syndromes. A special modification of the record was prepared for this study when the running subjective evaluations of the effect of the treatment by the patient, as obtained in the course of directed interviews, as well as objective results of somatic and laboratory changes including the aggregate yearly evaluation of the effect of the treatment in every individual woman of the series are clearly arranged.

Administration, Cutaneous↗
PubMed1977

[Autonomic-vascular and visceral crises in patients with climacteric spondylopathy].

The paper deals with the results of observations over 62 patients (55 females and 7 males) from the age of 42-76 with climacteric spondilopathy. The following syndromes of the nervous system lesions were revealed: neuralgic syndrome, middle and lower thoracal radiculoneuritis, the syndrome of vegetative sympatoganglionitis, myelopathy. Special attetion was given to the specificity of the nervous system lesions in patients with climacteric spondilopathy which was characterized by a tendency to vegetative-visceral crises. The author recommends a scheme of a comprehensive treatment of patients with climacteric spondilopathy with vegetative-vascular and visceral crises. This treatment includes androgen-estrogen preparations, anabolic steroids, thyrocalcitonine and symptomatic treatment.

Adult↗
PubMed1976

Difference between effects of conjugated estrogen on neurotics and non-neurotics of climacteric women complaining of menopausal symptoms and its clinical application for their screening.

In order to screen the neurotics and non-neurotics of climacteric women with menopausal symptoms, conjugated estrogen was injected intravenously and the reactions were compared. Menopausal symptoms were represented by Kupperman's menopausal index. After estrogen injection the non-neurotics showed a decrease of the index, i.e., alleviation of the symptoms, while the neurotics showed no change of the index. Taking advantage of this difference, a discriminant function between neurotics and non-neurotics was calculated using, as variables, Kupperman's menopasual indices determined before and after administration of the conjugated estrogen. The calculative screening obtained from this discriminant function yielded consistency with clinical diagnosis in about 94% of the neurotics and about 87% of the non-neurotics, suggesting that this test is of value in the screening of neurotics and non-neurotics in the climacteric women with menopausal symptoms.

Adult↗
PubMed1975

Treatment of climacteric complaints with oestriol.

150 women with serious climacteric complaints were continuously treated from January, 1970, up to April, 1972, with Ovestin¿, an orally effective preparation containing 1 mg of oestriol per tablet. After one month of treatment subjective complaints were already considerably improved. Oestrogenic activity was markedly increased, according to vaginal smears and total gonadotrophin excretion in the urine. Its high tolerance and beneficial therapeutic effect make Ovestin the preparation of choice in the treatment of the climacteric syndrome.

Adult↗
PubMed1992

[Prostaglandins PGF2alpha in the fight against bleeding and hemorrhage the uterus during the climacteric period].

This article is about usage prostaglandins to fight against bleeding and haemorrhage from uterus in climacteric period. Prostaglandins are used widely by gynecologist and obstetrics as most powerful contracting drugs, namely in this situations when we observe returning, plentiful bleeding from uterus. Women with climacteric bleeding had administer prostaglandins intravenous or immediate intra-cervix. They are very good drug, strongly and a long time hold up bleeding. This method give us time to better preparing patients to operation and diminish losses of blood. Side effects are small and not trouble. Prostaglandins are very simply in usage and characterise very good haemostatic effect, recognised faster then in typical methods like hormonal, mechanical antifibrinolytic etc.

Climacteric↗
PubMedDate not supplied

[The relation between dysmenorrhea and hot flash in a group of women in climacteric].

Hot flushes in climacteric age can cause noticeable discomfort to those who have them. This functional disturbance confirms the strong relationship between the gonadic steroids and the central neurotransmitters. These complex mechanisms which control reproductive functions limit our knowledge of the pathogenesis of hot flushes. The possible intervention of prostaglandins in the rising of this disturbance and their participation in dismenorrhea have raised the hypothesis that the prostaglandins may be the common denominator in the development of dysmenorrhea in fertile age women and of hot flushes in climacteric age women. Under this context, we examined a number of women in menopause to determine if they suffered with dysmenorrhea in fertile age.

Adult↗
PubMed1992

Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding.

Bone mass, calcium and lipid metabolism, climacteric symptoms, bleeding, blood pressure, and weight changes were studied in 62 healthy postmenopausal women at 3-month intervals throughout 2 years of treatment with continuous estradiol valerate (2 mg) plus cyproterone acetate (1 mg), sequential estradiol valerate (2 mg) plus levonorgestrel (75 micrograms), or placebo. During the 2 years of the study, bone mineral content of the distal and ultradistal regions of the forearm (measured by single-photon absorptiometry) remained unchanged in the hormone groups, whereas bone mineral content at these sites decreased by 5 and 6%, respectively, in the placebo group. Bone mineral density in the spine (measured by dual-photon absorptiometry and dual-energy x-ray absorptiometry) increased by 3-4% in the hormone groups and decreased by 2% in the placebo group. Biochemical estimates of bone turnover (serum alkaline phosphatase and fasting urinary calcium/creatinine) decreased significantly to premenopausal levels in the hormone groups, but remained unchanged in the placebo group. Serum concentrations of total and low-density lipoprotein cholesterol were significantly reduced by 5-10% (P less than .05-.01) in the estradiol + cyproterone acetate group and by 10-15% (P less than .001) in the estradiol valerate + levonorgestrel group. There were no significant changes in high-density lipoprotein cholesterol in the hormone groups. Virtually no changes were observed in the placebo group. Climacteric symptoms and hot flushes were significantly reduced in both hormone groups compared with the placebo group.(ABSTRACT TRUNCATED AT 250 WORDS)

Bone Density↗
PubMed1977

Menopause in rhesus monkeys: model for study of disorders in the human climacteric.

Hormonal and menstrual patterns were studied in rhesus monkeys 22 years of age or older. Sustained elevations of serum gonodotropins, low circulating levels of estradiol and progesterone, associated with oligomenorrhea or amneorrhea, were similar to changes reported for peri- and postmenopausal women. During the menopausal transition, pituitary FSH appears to be modulated independently of LH. These observations suggest that the rhesus monkey may be a suitable model for study of disorders afflicting women in the climacteric.

Animals↗
PubMed1978

Relation between plasma oestrone and oestradiol and climacteric symptoms.

Plasma levels of oestrone and oestradiol-17beta were determined at 20 or 30 minute intervals for up to 24 hours in 26 postmenopausal or ovariectomised women of similar age, weight, and number of years since menopause or operation. Results in women with both superficial dyspareunia and flushes were compared with those in women with flushes only, and with those in symptomless women. Women with superficial dyspareunia had significantly lower mean concentrations of plasma-oestradiol, but not of oestrone, than symptomless women. Flushes were not related to plasma-oestrogen. The implications of these findings in relation to the optimum dose of oestrogen for treating climacteric symptoms are discussed.

Adult↗